Related Experiment Video

Updated: Aug 30, 2026

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Growth factor receptor tyrosine kinase inhibitors; clinical development and potential for prostate cancer therapy

George Blackledge1

  • 1AstraZeneca, Alderley Park, Macclesfield, United Kingdom.

The Journal of Urology
|November 12, 2003
PubMed
Abstract

Insights

Targeted cancer therapies like gefitinib, which inhibit receptor tyrosine kinases, show promise. These novel treatments offer potential new options for various malignancies, including prostate cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Receptor tyrosine kinases (RTKs) are crucial in cell signaling pathways often dysregulated in cancer.
  • Targeting RTKs offers a strategy for developing novel, effective cancer therapies with potentially fewer side effects.
  • Angiogenesis and other tumor progression processes are influenced by RTK signaling.

Purpose of the Study:

  • To review the role of RTKs in human malignancies.
  • To discuss the potential of RTK inhibitors as anticancer agents.
  • To focus on gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor.

Main Methods:

  • Literature review on RTKs in human cancers.
  • Discussion of RTK inhibitors' therapeutic potential.
  • Focus on gefitinib's preclinical and clinical evaluation.

Main Results:

  • Small molecule RTK inhibitors are in development and clinical trials.
  • Gefitinib demonstrated potential in preclinical models of prostate cancer, both as monotherapy and in combination with bicalutamide.
  • Further evaluation of gefitinib for prostate cancer treatment is ongoing.

Conclusions:

  • Tyrosine kinase inhibitors, such as gefitinib, are advancing in clinical development.
  • These inhibitors represent emerging therapeutic options for diverse malignancies.
  • Targeted therapies are expanding treatment possibilities in oncology.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...